Ajanta Pharma Ltd
NSE:AJANTPHARM
Ajanta Pharma Ltd
Net Income (Common)
Ajanta Pharma Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ajanta Pharma Ltd
NSE:AJANTPHARM
|
Net Income (Common)
₹9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹53.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹49.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
25%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹114.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹18.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income (Common)
₹19.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ajanta Pharma Ltd
Glance View
In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.
See Also
What is Ajanta Pharma Ltd's Net Income (Common)?
Net Income (Common)
9B
INR
Based on the financial report for Dec 31, 2024, Ajanta Pharma Ltd's Net Income (Common) amounts to 9B INR.
What is Ajanta Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
16%
Over the last year, the Net Income (Common) growth was 22%. The average annual Net Income (Common) growth rates for Ajanta Pharma Ltd have been 8% over the past three years , 16% over the past five years .
You don't have any saved screeners yet